ROBERT COMIS, professor of medicine at Drexel University, will step down from his position as group co-chair of ECOG-ACRIN Cancer Research Group. His departure, effective Feb. 28, 2019, will coincide with the end of ECOG-ACRIN’s current National Clinical Trials Network Operations Center U10 grant award from the NCI. Comis chaired the Eastern Cooperative Oncology Group...
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.Â
